Boehringer Ingelheim describes it as a dual glucagon/GLP1 receptor agonist that has the potential to address obesity while also supporting liver function, a key regulator of metabolic health. The company links the waistcircumference reduction in SYNCHRONIZE1 to effects on visceral fat, noting that excess visceral fat, particularly abdominal, is a known contributor to metabolic dysfunction and closely connected to impaired liver function
My goal here is practical: to help you make an informed choice about your health by explaining the likely side effects and when they usually resolve
Sikiric, P., Seiwerth, S., Brcic, L., Sever, M., Klicek, R., Radic, B., & Kolenc, D
GSH is synthesized de novo in the brain by astrocytes and research has demonstrated increased GSH synthesis during oxidative stress-related toxicity in vitro , proposing in vivo synthesis of this antioxidant might be sufficient to not detect significant changes (14)
The primary endpoint was the mean change in HbA1c from baseline to week 40 to assess the non-inferiority of tirzepatide 10 mg and 15 mg ( These trials focused on evaluating the efficacy of tirzepatide in glycemic control and weight management, providing an effective treatment option for patients with type 2 diabetes and opening new possibilities for future cardiovascular health management
